Mirkin, Chad A.,Ko, Caroline H.,Stegh, Alexander,Giljohann, David A.,Luciano, Janina,Jensen, Sam
申请号：
AU2017216461
公开号：
AU2017216461B2
申请日:
2017.08.15
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
#$%^&*AU2017216461B220191017.pdf#####ABSTRACT Polyvalent nanoconjugates address the critical challenges in therapeutic use. The single-entity, targeted therapeutic is able to cross the blood-brain barrier (BBB) and is thus effective in the treatment of central nervous system (CNS) disorders. Further, despite the tremendously high 5 cellular uptake of nanoconjugates, they exhibit no toxicity in the cell types tested thus far. This property is critical for therapeutic agent delivery applications for reducing off-target effects.
